Telescope Innovations Corp. News Releases

Telescope Innovations to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Thu, 11 Jun 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of intelligent automation and advanced chemical manufacturing technologies, is pleased to announce it will be presenting at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17th, 2026. At Planet MicroCap, Dr. Jeffrey Sherman will provide an update on Telescope's business including its DirectInject-LC™...

Telescope Innovations Founder and CTO, Professor Jason Hein, Receives 2026 SCI Canada LeSueur Memorial Award

Fri, 05 Jun 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") congratulates its Founder and Chief Technology Officer, Professor Jason Hein, on receiving the 2026 SCI Canada LeSueur Memorial Award from the Society of Chemical Industry ("SCI").Figure 1. The 2026 LeSeueur Memorial Award Presented to Professor Jason HeinTo view an enhanced version of this graphic, please...

Telescope Innovations Secures Third Self-Driving Lab Deployment with Major Global Pharmaceutical Company

Mon, 01 Jun 2026 08:00:00 -0400

Continued adoption by world-leading pharmaceutical partners underscores growing industry demand for autonomous lab technology Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of intelligent automation and advanced chemical manufacturing technologies, today announced that is has signed an agreement with a major global pharmaceutical company to deliver a Self-Driving...

Telescope Innovations Shares Spring 2026 Conference and Events Lineup

Mon, 11 May 2026 08:00:00 -0400

The Company is actively engaging with pharmaceutical, academic, and investor audiences to strengthen existing and novel partnerships Vancouver, British Columbia--(Newsfile Corp. - May 11, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a developer of enabling technologies and services for the global pharmaceutical and high value chemical industries. The Company is pleased to report on outreach, marketing, and educational activities,...

Telescope Innovations Provides Financial Results of Second Fiscal Quarter 2026

Mon, 13 Apr 2026 18:00:00 -0400

Revenues are consistent with budget expectations and ahead of Q2 2025 comparative revenues Vancouver, British Columbia--(Newsfile Corp. - April 13, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended February 28, 2026 (Q2 FY2026). The Company generated revenues of approximately $1.6...

Telescope Innovations Announces Expansion of Consulting Role for Dr. Joel M. Hawkins, Industry Leader in Process Chemistry Automation

Mon, 23 Mar 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a developer of enabling technologies and services for the global pharmaceutical and high value chemical industries. The Company is pleased to announce that Dr. Joel M. Hawkins has expanded his consulting role with Telescope. Dr. Hawkins is an industry-wide authority in automating complex chemistry workflows and enabling the...

Telescope Innovations and AGI SDA Launch Technology Development Collaboration

Mon, 16 Mar 2026 08:00:00 -0400

The chemistry technology companies aim to develop a next-generation chemical reactor for automated labs Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a developer of enabling technologies and services for the global pharmaceutical and high value chemical industries, with established leadership in sampling systems for monitoring chemical and biological processes. The Company is...

Telescope Strengthens Investor Communications Strategy

Thu, 12 Mar 2026 08:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (the "Company"), a leading developer of advanced technologies and services for the global pharmaceutical and high-value chemical industries,has rescoped its previously announced digital marketing agreement dated September 19, 2025, with Gold Standard Media, LLC ("GSM") and its affiliates. In connection with the reduction in scope GSM has refunded the Company $300,000...

Telescope Innovations Installs Second Self-Driving Lab at Pfizer

Mon, 23 Feb 2026 08:00:00 -0500

Installation of second Physical AI platform positions Telescope Innovations to successfully address the rapidly expanding SDL market Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the installation of its second Self-Driving Laboratory ("SDL") at Pfizer,...

Telescope Innovations Delivers Continued Strong Sales Revenue Growth in First Fiscal Quarter 2026

Fri, 30 Jan 2026 19:28:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE:J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended November 30, 2025 (Q1). The Company generated revenues of $2.7 million during this period, driven by continued market adoption of its flagship product, DirectInject-LC™,...